• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

“CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial” published in “The Lancet Haematology”.

February 20, 2023 By

    https://doi.org/10.1016/S2352-3026(22)00378-7

    Footer

    Celyad Oncology

    Celyad Oncology Logo
    • About
    • Science
    • Pipeline
    • Newsroom
    • Investors
    • Contact Us
    • LinkedIn
    • Twitter

    Copyright © 2020 All Rights Reserved.

    • Cookie Policy |
    • Privacy Policy |
    • Terms of Use